Mar 26, 2019 - Top Research Reports for Apple, Amgen & United Technologies
Mar 18, 2019 - Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Mar 15, 2019 - Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.
Mar 15, 2019 - BMO Capital Markets issues rating change for AMGN
Mar 14, 2019 - Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.
Mar 12, 2019 - Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.
Mar 11, 2019 - The largest biotech ETF looks good for investors who don't mind the industry's manic behavior.
Mar 06, 2019 - Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
Mar 06, 2019 - Ligand Pharmaceuticals (LGND) announces sale of all rights to Novartis' Promacta, including royalty payments on global sales, to Royalty Pharma.
Mar 06, 2019 - Pharmaceutical companies are suddenly eager to lower drug prices.